

# Cefalexin

## Newborn use only

2020

<b>Alert</b>	High risk medicine. The Antimicrobial Stewardship Team recommends this drug is listed under the following category: Unrestricted.												
<b>Indication</b>	Treatment of mild infections due to susceptible strains of bacteria. Prophylaxis of urinary tract infections in patients at risk, such as vesicoureteric reflux.												
<b>Action</b>	First generation cephalosporin. Bactericidal – inhibits cell wall synthesis in susceptible organisms. Most active against Gram-positive cocci, including MSSA and streptococci. Has have no activity against enterococci, MRSA or <i>Listeria</i> . <sup>1</sup>												
<b>Drug type</b>	Cephalosporin antibiotic.												
<b>Trade name</b>	APO-Cephalexin, Cefalexin Sandoz, Ialex, Ibilex, Keflex.												
<b>Presentation</b>	125 mg/5 mL suspension 250 mg/5mL suspension												
<b>Dose</b>	<p><b>Treatment</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: center;">Postnatal Age (Days)</th> <th style="text-align: center;">Dose</th> <th style="text-align: center;">Interval</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">0–7 days</td> <td style="text-align: center;">25 mg/kg</td> <td style="text-align: center;">12-hourly</td> </tr> <tr> <td style="text-align: center;">8–28 days</td> <td style="text-align: center;">25 mg/kg</td> <td style="text-align: center;">8-hourly</td> </tr> <tr> <td style="text-align: center;">≥29 days</td> <td style="text-align: center;">25 mg/kg</td> <td style="text-align: center;">6-hourly</td> </tr> </tbody> </table> <p><b>Prophylaxis of urinary tract infection (UTI)</b> 12.5 (10–15) mg/kg/dose DAILY (maximum dose 125 mg daily).<sup>7,8</sup></p> <p><b>Prophylaxis around Micturating Cystourethrogram (MCU)</b> 12.5 (10–15) mg/kg/dose 8-hourly for 3 days (day prior, on the day and one day after MCU).<sup>10</sup></p>	Postnatal Age (Days)	Dose	Interval	0–7 days	25 mg/kg	12-hourly	8–28 days	25 mg/kg	8-hourly	≥29 days	25 mg/kg	6-hourly
Postnatal Age (Days)	Dose	Interval											
0–7 days	25 mg/kg	12-hourly											
8–28 days	25 mg/kg	8-hourly											
≥29 days	25 mg/kg	6-hourly											
<b>Dose adjustment</b>													
<b>Maximum dose</b>	500 mg												
<b>Total cumulative dose</b>													
<b>Route</b>	Oral												
<b>Preparation</b>	Supplied reconstituted by Pharmacy. If supplied unreconstituted, use water for injection with the volume specified on the packaging for reconstitution.												
<b>Administration</b>	Shake bottle well before measuring dose. Prophylactic dose: May be taken with or without food. Treatment dose: Preferably commence treatment <b>without</b> feeds for faster absorption and higher peak concentrations <sup>3</sup>												
<b>Monitoring</b>	Renal, hepatic and haematological function with prolonged use.												
<b>Contraindications</b>	Hypersensitivity to cephalosporins. Immediate hypersensitivity or severe reaction to penicillins.												
<b>Precautions</b>	Use with caution in patients with hypersensitivity or mild adverse reactions to penicillins or carbapenems as cross-reactivity can occur (e.g. rash).												
<b>Drug interactions</b>	Not applicable.												
<b>Adverse reactions</b>	Diarrhoea, abdominal pain, vomiting. Pseudomembranous colitis (rare). Transient elevation of liver enzymes. Hypersensitivity: Immediate – urticaria, bronchospasm, anaphylaxis. Delayed – maculopapular rash, fever, eosinophilia.												
<b>Compatibility</b>	Not applicable.												
<b>Incompatibility</b>	Not applicable.												
<b>Stability</b>	Reconstituted solution should be discarded after 14 days.												
<b>Storage</b>	Store powder below 25°C Store reconstituted solution between 2 and 8°C												
<b>Excipients</b>													
<b>Special comments</b>	May cause false positive Coombs test. Consider increasing dosing interval in significant renal impairment.												

<b>Evidence</b>	Refer to full version.
<b>Practice points</b>	Refer to full version.
<b>References</b>	Refer to full version.

<b>VERSION/NUMBER</b>	<b>DATE</b>
<b>Original 1.1</b>	<b>08/08/2015</b>
<b>Version2.0</b>	<b>20/05/2019</b>
<b>Version 3.0</b>	<b>16/12/2020</b>
<b>Review</b>	<b>16/12/2025</b>

**Authors Contribution**

<b>Original author/s</b>	Chris Wake, Srinivas Bolisetty
<b>Evidence Review</b>	David Osborn
<b>Expert review</b>	Brendan McMullan, Sean Kennedy, Anne Durkan
<b>Nursing Review</b>	Eszter Jozsa, Kirtsy Minter
<b>Pharmacy Review</b>	Jing Xiao, Michelle Jenkins, Cindy Chen
<b>ANMF Group contributors</b>	Nilkant Phad, Himanshu Popat, Rajesh Maheshwari
<b>Final editing and review of the original</b>	Ian Whyte
<b>Electronic version</b>	Cindy Chen, Ian Callander
<b>Facilitator</b>	Srinivas Bolisetty